证券代码：600085 证券简称：同仁堂 公告编号：2025-004 北京同仁堂股份有限公司 第十届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司）第十届董事会第七次会议于 2025 年 4 月 2 日在公司会议室以现场结合通讯会议方式召开。本次会议通知已提前送 达全体董事，与会各位董事均已知悉与本次会议所议事项的相关必要信息。本次 董事会会议应出席董事 11 人，实际出席 11 人。公司全体监事及部分高级管理人 员列席了本次会议。会议由董事长邸淑兵先生主持，会议的召开和表决程序符合 《中华人民共和国公司法》及《北京同仁堂股份有限公司章程》的有关规定。 二、会议审议情况 (一) 审议通过了《2024 年度总经理工作报告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 (二) 审议通过了《2024 年度财务决算报告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 (四) 审 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-006 北京同仁堂股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金红利 0.50 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记日前，北京同仁堂股份有限公司（以下简称公司） 的总股本如发生变动的，拟维持分配总额不变，相应调整每股分配比例，并将另 行公告具体调整情况。 公司未触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示 的情形。 一、利润分配预案内容 (一) 利润分配方案的具体内容 经中审众环会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 公司合并报表期末未分配利润为人民币 8,386,175,950.07 元，母公司报表中期末 未分配利润为人民币 3,804 ...

Financial Performance - The company's operating revenue for 2024 reached CNY 1,859,728.16 million, representing a 4.12% increase compared to CNY 1,786,089.15 million in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 152,627.49 million, a decrease of 8.54% from CNY 166,883.45 million in 2023[23]. - The net cash flow from operating activities for 2024 was CNY 76,098.53 million, down 59.29% from CNY 186,949.19 million in 2023[23]. - The total assets as of the end of 2024 amounted to CNY 3,119,752.40 million, an increase of 3.68% from CNY 3,008,945.02 million at the end of 2023[23]. - Basic earnings per share for 2024 decreased by 8.55% to CNY 1.113 compared to CNY 1.217 in 2023[24]. - The weighted average return on equity fell to 11.49% in 2024, down 1.93 percentage points from 13.42% in 2023[24]. - The total cash dividends distributed to shareholders for 2024 will amount to CNY 1,371,470.26 million, representing 89.86% of the net profit attributable to shareholders[7]. - The company has completed its semi-annual profit distribution for 2024, totaling CNY 685,735.13 million[7]. Operational Highlights - The company has maintained a consistent growth trajectory in total assets over the past three years, increasing from CNY 2,705,412.32 million in 2022 to CNY 3,119,752.40 million in 2024[23]. - The company has not reported any significant risks that could materially affect its operations during the reporting period[10]. - The company is focusing on high-quality development and implementing its "14th Five-Year Plan" goals, emphasizing service and innovation[34]. - The company aims to enhance its image and service capabilities through strategic initiatives and party leadership integration[34]. - The company is actively exploring multi-dimensional cooperation models to accelerate project implementation and development of new productive forces[34]. - The company has established a professional medical team and sales channels to expand its business in the medical field, focusing on developing core markets such as hospitals and community medical institutions[37]. Research and Development - The company is focusing on R&D projects for new products and secondary development of existing products, including the classic prescription and key varieties like Ba Jitian oligosaccharide capsules[84]. - The company has several ongoing clinical studies for new products, including the Renshen Guipi Wan and Tianwang Buxin Wan, which are expected to enhance market offerings[85]. - The company’s R&D investment amounted to 2,314.68 million RMB for clinical research on various products, reflecting an increase of 89.72% compared to the previous year[94]. - The company is actively pursuing R&D in traditional Chinese medicine, with a focus on integrating key technology for production quality control[84]. - The company’s R&D investment as a percentage of net assets was 1.96%, indicating a moderate level of investment relative to its asset base[92]. Market Expansion and Strategy - The company actively expanded its overseas market presence, with products like Yang Yin Qing Fei Wan and Shi Yi Qing Wen Wan receiving product registration in Canada[42]. - The company is focusing on enhancing its e-commerce channels and has partnered with platforms like JD Health and Alibaba Health for cross-border sales[41]. - The company is committed to the internationalization of traditional Chinese medicine, leveraging brand culture and public welfare initiatives to enhance market promotion[41]. - The company is focusing on expanding its market presence and enhancing its competitive edge through strategic mergers and acquisitions[110]. - The company aims to accelerate the upgrade of its entire industry chain and improve innovation efficiency in response to market demands and policy support[111]. Environmental and Social Responsibility - The company invested 34.39 million yuan in environmental protection during the reporting period[181]. - Total wastewater discharge was 356,900 tons, with COD emissions of 237,100 tons and ammonia nitrogen at 2,680 tons, all within regulatory limits[182]. - The company has established wastewater treatment facilities at all branches, which are operated by a professional company and are functioning normally[184]. - The company has committed to resolving any potential industry competition issues arising from its acquisition of a 60% stake in Tianjin Tongrentang Group[200]. - The company has actively engaged in ESG practices, receiving recognition as an outstanding case in ESG responsibility and governance awards for its sustainable development efforts[40]. Governance and Compliance - The company has established a robust internal control system to enhance information disclosure quality and protect the rights of all shareholders[125]. - The board of directors is responsible for strategic decision-making and risk management, with specialized committees in place to support effective governance[126]. - The company is committed to legal compliance and has established a legal advisory system to ensure lawful operations and management[127]. - The company has a comprehensive evaluation system for the legal compliance of its subsidiaries, achieving a 100% coverage rate[178]. - The company has not faced any penalties from securities regulatory authorities in the past three years[147].

Core Strategy - The company is focusing on its "big product" strategy, reallocating resources to core products that demonstrate strong market potential and clinical value [1][2] - Since the implementation of the "big product" strategy in 2020, the company has identified over 20 high-value traditional Chinese medicine products from nearly 200 options, categorized into various therapeutic series [1] Product Development - The company has selected five core products, including Jingzhi Niuhuang Jiedu Pian and Liuwei Dihuang Wan, and is implementing differentiated marketing strategies to enhance their market share [2] - The "Yuyao 300 Years" series is being positioned as a key component of marketing activities, aiming to strengthen market presence through partnerships with major retail chains [2] Market Expansion - The company plans to cultivate a range of small to medium-sized products that align with market demands, focusing on preventive health interventions [2] - In the non-pharmaceutical sector, the company aims to explore market potential for health products like Ejiao food series and Pi Pa Lu, leveraging existing sales channels for broader market reach [2]

而同仁堂科技深受合作伙伴欢迎，频频打开市场与渠道空白点的"插旗行动"也将在今年推出升级版，活 动将以"成熟市场巩固，空白市场不白"为原则，以京制牛黄解毒片、西黄丸、感冒清热颗粒、六味地黄 丸、加味逍遥丸等核心品种为突破口，进一步拓宽活动的深度和广度，向消费者传递产品信息、健康知 识等，提升品牌形象，促进产品销售。 "营销模式的调整要跟得上市场的变化。"同仁堂科技相关负责人表示，企业将进一步推动营销模式向着 更灵敏的方向转型，以高效的"扁平化"配置为出发点，缩短销售链条，提高流通效率，同时持续优化各 品种的控销效果，加强对产品、价格、渠道、终端和市场的全面掌控，逐步搭建更为良性立体的品种发 展生态，充分释放品牌优势和市场潜力。 为了达到提升"渠道盈利能力"这一目标，同仁堂科技在年初已对战略合作伙伴、终端渠道、电商渠道等 资源进行深度整合，根据不同区域、不同品类、不同渠道精准施策，给予营销资源倾斜。 以终端门店为例，企业发力打造单体旗舰店，出台标准化的管理流程，规范品种经营数量、活动开展、 产品码放等方面要求，并为旗舰门店提供定制促销品、路演活动、落地广告投放等全方位终端支持。据 了解，合作粘性高的旗舰店还将嵌入 ...

Core Insights - Tong Ren Tang Guo Yao achieved a revenue of HKD 1.612 billion, representing a year-on-year growth of 5.7%, and a net profit of HKD 529 million for the reporting period [2] Group 1: Business Performance - The company launched several new products, including the NMN anti-aging series and other traditional Chinese medicine products, enhancing its product matrix [3] - Revenue from the Hong Kong market reached HKD 1.07 billion, showing a significant year-on-year increase of 16.9% despite challenges in the retail sector [6] - The company expanded its retail presence in Hong Kong, increasing the number of retail terminals to 29, a net addition of 2 stores compared to the previous year [6] Group 2: Research and Development - Tong Ren Tang Guo Yao strengthened its R&D efforts, achieving significant results in product innovation and safety studies, including the approval of Danggui Blood Supplement Granules [3][4] - The company signed a cooperation agreement with Macau University of Science and Technology to enhance research collaboration and product registration [3] Group 3: Marketing and Brand Promotion - The company actively engaged in marketing activities, including the "Tong Ren Tang Day" and the "9th Tong Ren Care Against Stroke" series, to promote its brand and cultural heritage [5][7] - Tong Ren Tang Guo Yao emphasized its commitment to public welfare as a core aspect of its brand culture, conducting health-related activities in collaboration with local institutions [7] Group 4: Future Outlook - For 2025, the company aims to focus on "adjustment and recovery, cost reduction, and efficiency enhancement," implementing strategies to optimize management, products, investments, and finances [7]

"同仁堂科技"（01666.HK）"安宫牛黄丸"产能提升项目中的关键节点——新增生产线，已经通过药监部 门GMP认证。这标志着生产现场、设备设施等软、硬件准备已全部就绪。在拿到药监部门的证书后， 新线即可投入生产。届时，产能预计将实现30%以上的提升。 安宫牛黄丸是同仁堂的明星产品。近年来，市场对安宫牛黄丸的关注度不断提高，需求也随之增高。观 研报告网发布的《中国安宫牛黄丸行业发展现状分析与未来前景预测报告（2023—2030年）》显示，在 这一细分市场，同仁堂目前占据的市场份额约50%。 新增的生产线，对生产面积进行了扩容，在生产布局上进行了优化调整，实现了从合坨工序到外包工序 均位于同一楼层，有效缩短了各工序之间的距离，从而提高了整体生产效率。企业还引入了全新的智能 为进一步满足市场需求，同仁堂科技加速推动产能提升。企业相关负责人表示，此前存量的安宫牛黄丸 生产线需要在"天然方"（天然牛黄、天然麝香）安宫牛黄丸和"体培方"安宫牛黄丸（体外培育牛黄、人 工麝香）两个品类之间进行切换。在新增生产线后，产线分工将更为明确，一条产线只负责一个品类的 生产，减少了不同品类"切换"生产带来工作量，"专一提升效率，更可 ...

Group 1 - The core viewpoint of the article emphasizes the potential investment opportunities in Tong Ren Tang Guo Yao, driven by its solid financial performance and growth prospects in the traditional Chinese medicine sector [1][2][3] - The company reported a revenue of HKD 1,611.6 million for 2024, a 5.7% increase from HKD 1,524.9 million in 2023, with significant growth in the Hong Kong market [3][4] - The compound annual growth rate (CAGR) for revenue since its listing in 2013 is 8.38%, while net profit CAGR is 7.27%, indicating a stable growth trajectory [4] Group 2 - The company maintains a low debt ratio of 2.9% and has a strong cash flow, with cash and cash equivalents amounting to HKD 18.20 billion in 2024 [5] - The gross profit margin has averaged around 69% over the past five years, supported by key products like An Gong Niu Huang Wan and Lingzhi, which contribute significantly to cash accumulation [4][5] - The dividend payout ratio for 2024 reached 58.6%, reflecting the company's commitment to returning value to shareholders [5] Group 3 - The traditional Chinese medicine industry is expected to experience accelerated growth due to increasing recognition of Chinese medicine culture and supportive government policies [6] - The market for traditional Chinese medicine in China is projected to exceed CNY 1 trillion in 2023, driven by an aging population and rising health awareness [6] Group 4 - An Gong Niu Huang Wan, a core product of the company, has a strong brand presence and is recognized for its unique therapeutic properties, contributing to a solid competitive advantage [7][8] - The company is expanding its overseas market presence, with over 160 retail outlets established across various regions, including Asia, Oceania, North America, and Europe [12] Group 5 - The company is actively pursuing product registration in international markets, enhancing its global footprint and tapping into the growing demand for traditional Chinese medicine [13][14] - Recent collaborations with academic institutions aim to modernize traditional Chinese medicine and facilitate its acceptance in Western markets [14] Group 6 - The company is focusing on product innovation, launching new products such as anti-aging series and herbal formulations, which are expected to enhance its product portfolio [15][16] - The company is also strengthening its online sales channels, partnering with major e-commerce platforms to expand its market reach [17] Group 7 - The Hong Kong pharmaceutical sector is undergoing a revaluation, with Tong Ren Tang Guo Yao positioned as a strong candidate for investment due to its growth potential and historical low valuation [18][19] - The company is anticipated to benefit from a "Davis Double Play," where both valuation and performance are expected to improve simultaneously [20]

Group 1 - The core viewpoint of the news is that Tongrentang Technology has made significant progress in its traditional Chinese medicine processing project in Yutian, Hebei, with over 50 sets of equipment successfully installed and operational work underway [1][2][3] Group 2 - In 2024, coinciding with the 10th anniversary of the Beijing-Tianjin-Hebei coordinated development strategy, Tongrentang Technology has initiated the construction of a traditional Chinese medicine processing workshop to enhance its processing capacity and optimize its industrial layout [2] - The project is located in the National Agricultural Science and Technology Park in Yutian County, Tangshan City, covering an area of 80 acres, primarily focusing on the preparation of raw medicinal materials [2] - The first phase of the project includes three main buildings: Factory 1, Pre-treatment Workshop 2, and Raw Material Storage 3, along with eight auxiliary buildings [2] Group 3 - Since the project's launch, multiple construction milestones have been successfully achieved, with all three main buildings completed and finishing touches on decoration and renovation underway [3] - The successful installation of production equipment marks a critical milestone, bringing the project closer to completion and production [3] - Once phase one is completed, the production base will have the capacity to produce 4 million kilograms of processed medicinal materials annually, enhancing the company's processing capabilities and supply capacity [3]

Core Viewpoint - Tongrentang Technology reported a revenue of 7.26 billion and a net profit of 0.887 billion for the fiscal year 2024, demonstrating resilience in a challenging pharmaceutical market environment [1] Group 1: Financial Performance - The company achieved a revenue of 7.26 billion and a net profit of 0.887 billion during the reporting period [1] - Despite challenges such as rising raw material prices and decreased foot traffic in stores, the company improved its overall operational quality [1] Group 2: Innovation and R&D - Tongrentang Technology increased its investment in research and development, accelerating the development of innovative drugs and classic formulas [2] - The company received clinical trial approval for Qishen Granules, marking its first clinical approval for a traditional Chinese medicine in eight years [2] - Several products underwent pharmacological mechanism studies, enhancing their market competitiveness and clinical recognition [2] Group 3: Market Strategy and Product Expansion - In response to external challenges, the company adjusted its market strategy, focusing on channel management, price stability, and terminal empowerment [3] - The company launched promotional activities for its "Yuyao 300" product line, resulting in nine products exceeding 0.1 billion in sales [3] Group 4: Channel Development - Tongrentang Technology strengthened its partnerships with major distributors and conducted over 450 promotional events in previously untapped markets [4] - The company aimed to enhance product distribution rates and terminal effectiveness through targeted market strategies [4] Group 5: Risk Management and Future Plans - The company plans to enhance its governance and core competitiveness to address risks and challenges [5] - Future initiatives include a new round of collaborative innovation in traditional Chinese medicine, aiming to complete clinical research on five products by 2025 [5]